BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16

• 

  Immuno-oncology

  Cartography Pushes Sequencing to the Limit To Find Bananas in 100 Apples

  The startup, launched out of CEO Kevin Parker’s grad school idyll during the COVID lockdowns, is primed to find new targets where Big Pharmas won’t dare.

  October 15, 2025

   · 

  4 min read

   · 

  Dan Samorodnitsky
• 

  Career Advice

  Job Hugging Won’t Save You: The Hidden Risk of Playing It Safe

  In a volatile industry, staying put might seem like a smart bet, but job hugging can quietly erode your visibility, growth and future opportunities.

  October 15, 2025

   · 

  3 min read

   · 

  Angela Justice
• 

  Job search strategy

  More Marathon Than Sprint: Getting Biopharma Jobs Often Takes 4+ Months, BioSpace Finds

  Biopharma professionals aren’t typically hired right away, based on a BioSpace LinkedIn poll. In the past year, only about one-third of respondents found employment in three months or less. Several who did share their keys to success.

  October 15, 2025

   · 

  5 min read

   · 

  Angela Gabriel
• 

  Podcast

  Q3 Earnings Are Here, Novo Ditches Cell Therapy but Buys Akero, Gov’t Shutdown Hits CDC

  Johnson & Johnson has yet to make a drug pricing deal with Trump; Novo makes more moves under new CEO; more than 1,000 laid off from CDC, though many immediately hired back; the BIOSECURE Act is back and more.

  October 15, 2025

   · 

  1 min read

   · 

  Heather McKenzie
• 

  Gene therapy

  FDA’s Second Platform Designation Goes to Krystal After Sarepta Withdrawal

  After the FDA revoked Sarepta Therapeutics’ platform designation in July, Krystal Biotech is “poised to be the first major beneficiary” of this program, according to analysts at William Blair.

  October 15, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Mergers & acquisitions

  BioCryst Snaps Up Fellow Angiodema Player Astria for $700M

  The acquisition will give BioCryst an investigational injectable drug for hereditary angioedema, potentially complementing its FDA-approved oral drug Orladeyo.

  October 15, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  ALS

  BMS Deepens ALS Alliance With Insitro, Puts $2B+ On the Line

  Bristol Myers Squibb and insitro first partnered in 2020 to develop induced pluripotent stem cell models of amyotrophic lateral sclerosis and frontotemporal dementia. Last December, BMS exercised its option for an ALS target.

  October 15, 2025

   · 

  1 min read

   · 

  Tristan Manalac
• 

  Collaboration

  Boehringer Ingelheim Bets up to Nearly $1B in ADC Play With AimedBio Deal

  2025 has been a busy year for Boehringer Ingelheim, which has so far inked at least five hefty partnerships—including its latest one with South Korea’s AimedBio for an antibody-drug conjugate therapy for cancer.

  October 15, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  C-suite

  Biotech Leader Gujrathi Holds Up a Mirror for Other Women

  Sheila Gujrathi, former CEO of Gossamer Bio, has written a new book that aims to offer the type of leadership manual she never had in her early career.

  October 15, 2025

   · 

  5 min read

   · 

  Annalee Armstrong
• 

  Funding

  Pelage Pharmaceuticals Raises $120 Million To Grow Hair Loss Program

  The company is pursuing a Phase III trial for its topical stem cell-rejuvenating molecule that aims to reactivate hair growth.

  October 15, 2025

   · 

  2 min read

   · 

  Dan Samorodnitsky